SP 3164
Alternative Names: DRX-164; SP-3164Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator DeuteRx
- Class Antineoplastics; Piperidones; Quinazolines; Small molecules
- Mechanism of Action CRBN protein modulators; IKZF1 protein degraders; IKZF3 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- No development reported Solid tumours
Most Recent Events
- 22 Jan 2025 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (PO), prior to January 2025 (Salarius Pharmaceuticals pipeline, January 2025)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)